Home / Health / Astria Therapeutics' Navenibart Delivers Impressive Results for Hereditary Angioedema
Astria Therapeutics' Navenibart Delivers Impressive Results for Hereditary Angioedema
1 Aug
Summary
- Positive initial results from ALPHA-SOLAR trial of navenibart in HAE patients
- 92% mean and 97% median reduction in monthly HAE attack rate
- Potential for 3-month and 6-month dosing regimens, favorable safety profile
In a significant development, Astria Therapeutics has announced positive initial results from the ALPHA-SOLAR long-term trial of its medication navenibart (STAR-0215) for the treatment of hereditary angioedema (HAE). The findings, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, demonstrate an impressive overall reduction in the monthly HAE attack rate, with a 92% mean and 97% median reduction.
These results support the potential for both every three-month and every six-month dosing regimens for navenibart, as well as its favorable safety and tolerability profile. The ALPHA-SOLAR trial is a long-term, open-label study designed to assess the safety and efficacy of navenibart in adults with HAE Type 1 or 2. All 16 participants from the previous Phase 1b/2 ALPHA-STAR trial opted to enroll in ALPHA-SOLAR, further validating the promise of this medication.
Astria Therapeutics, a biopharmaceutical company focused on allergic and immunological diseases, is poised to build on these positive findings as it continues to develop and commercialize navenibart for the benefit of HAE patients in the United States.
